Galactomannan (GM) assay is commonly used as an early diagnostic tool for invasive fungal infection (IFI) in high-risk hematology patients. False positivity is frequently observed in GM with the use of piperacillin/tazobactam. The usage of generic drugs over the original brand has a significant cost advantage. The aim of this study was to assess the performance of GM test among patients receiving original and generic piperacillin/tazobactam formulations. The study included 85 adult patients; 62.4% were male with hematological malignancy currently receiving piperacillin/tazobactam. The study group was divided into two groups: patients receiving original and generic piperacillin/tazobactam. Serum GM index was positive in one of 35 patients receiving original piperacillin/tazobactam, whereas it was positive in 46 out of 50 patients receiving generic piperacillin/tazobactam (P < .001). However, the patients receiving generic piperacillin/tazobactam underwent computed tomography (CT) scans more frequently than those receiving original piperacillin/tazobactam (P = .047). In addition, in vitro analysis of GM was performed in two generics and one original piperacillin/tazobactam vials. One generic piperacillin/tazobactam vial included high GM level. False positivity of serum GM with generic formulations of piperacillin/tazobactam is still an ongoing issue in hematology patients. A high rate of serum GM index false positivity may unexpectedly lead to a higher rate of CT scan. Selected piperacillin/tazobactam vials in each batch should be checked for GM to identify a false positivity of GM before purchase.
Introduction
Invasive aspergillosis (IA) occurs in about 8-15% of patients undergoing allogeneic stem cell transplantation. 1 The treatment of IA is challenging in immunocompromised patients as it poses a nonspecific diagnostic sign and symptoms. Nonetheless, early diagnosis and initiation of an appropriate antimicrobial therapy may result in improved survival rates in these patients. The most commonly used tool for early diagnosis of IA in high-risk hematology patients is a galactomannan (GM) antigenemia test. 2 GM is a component of Aspergillus spp. cell wall that is released during fungal growth. 3 GM in human sera can be detected by a double-sandwich ELISA technique in which the monoclonal antibody binds to galactofuran epitope of GM antigen. 4 The false positivity of GM is a significant problem that limits the use in clinical settings. Many factors that lead to GM false positivity have been observed in some antimicrobial drugs such as piperacillin/tazobactamand amoxicillin/clavulanate. 5 The serum GM false positivity with piperacillin/tazobactam was recently clarified with the new formulation that contains ethylene diamine tetra acetylene (EDTA). 6, 7 However, false positivity continues to be a problem in generic formulas that are widely used in low-and middle-income countries. 8, 9 By using generic piperacillin/tazobactam in hematology units may lead to a substantial hospital cost from the economic point of view and compare. The aim of this study was to evaluate the effects of the original and generic piperacillin/tazobactam usage on GM test results.
Patients and methods
This study was conducted in patients admitted to Hematology and Hematopoietic Stem Cell Transplantation (HSCT) Unit at Erciyes University, Kayseri, Turkey. The HSCT unit consists of three floors with a 28-bed capacity that has positive pressure air circulation filtered by a high-efficiency particulate air (HEPA) filter in all rooms. Antimicrobial prophylaxis was administered to all the patients undergoing allogeneic or autologous HSCT according to the guidelines. 10 Patients' records were screened for criteria (i) receiving piperacillin/tazobactam formulations (ii) on febrile neutropenia and existing results of the GM antigenemia test during two periods including January-February 2015 (first period) and May 2015 (second period). The patients in the first period received the original piperacillin/tazobactam, and in the second period they were receiving one type generic piperacillin/tazobactam (G1). Patients that received antimicrobial therapy other than piperacillin/tazobactam were excluded from the study. This study was approved by Erciyes University's Ethics Committee (decision no: 2016/133). ) that are routinely used in the hematology unit were retrieved from the wards and tested for the GM antigen. The vials containing 4.5 g piperacillin/tazobactam (4 g piperacillin sodium and 500 mg tazobactam sodium) were resuspended in 100 ml of normal saline as performed in routine practice at the clinic; a sample of 5 ml from each vial were used for GM analysis. Samples from piperacillin/tazobactam vials were mixed with sera (taken from healthy adults) that were previously pretested and shown to be negative for GM antigen in order to prevent the drug-laboratory interaction in a clinical sample. The GM antigen levels were determined by using Platelia Aspergillus ELISA kit (Bio-Rad Laboratories, Marnes-la-Coquette, France) in accordance with the manufacturer's instructions. All serum samples of patients were kept at 2 to 8
• C prior to testing. All serum samples and piperacillin/tazobactam vials were studied for GM level at the Department of Medical Microbiology Mycology Laboratory. 7, 15 The GM index level ≥0.5 were considered to be positive. 16 
Statistical analysis
All data with normal distribution were analyzed by using t test, χ 2 , or Fisher exact test when appropriate. Data are presented as mean and standard deviations for parametric analyses. A P value < .05 was considered as statistically significant.
Results
During the study, 85 patients received piperacillin/ tazobactam due to febrile neutropenia including 35 patients in the first period and 50 patients in the second period. The mean age was 45.6 years; 53 patients (62.4%) were male; 41 of all patients (48.2%) had acute leukemia. The malignity status of the patients was: 56.4% of patients were experiencing recurrence of the relapsed disease, 36.5% were in remission. Forty-nine patients (57.6%) were stem cell transplantation recipients. At our center, original piperacillin/tazobactam was used for 35 patients during the first period. Only one positive result of GM index (1.24) was observed in patients receiving piperacillin/tazobactam. The mean serum GM level was 0.28 (range, 0.14-1.24). The median age was 50 years (range, 18-76 years) and 57.2% of the patients were male. Acute leukemia (42.9%) was the most common underlying disease, followed by myeloma (28.6%), lymphoma (17.1%) and myelodysplastic syndrome (11.4%). There were 13 allogeneic HSCT recipients; of these five were haploidentical recipients. However, there were four autologous HSCT recipients (Table 1) . Twenty-three patients received an antifungal agent including fluconazole in 13 patients, voriconazole in seven patients, liposomal amphotericin B (LamB) in two patients, caspofungin in one patient, and posaconazole in one patient before the serum GM test. No diagnosis of invasive fungal infection (IFI) was made in 25 patients (71.4%), whereas three patients were diagnosed for possible and probable IFI. Seven patients received mold active antifungal agents including voriconazole (n = 5) and LamB (n = 2). Voriconazole was given to three patients who were diagnosed as possible and probable IFI. When potential source of infection was assessed in patients with febrile neutropenia, no etiology was detected in 22 patients (62.9%), whereas cytomegalovirus viremia was detected in six patients (17.7%), bacteremia in four patients (11.4%), pneumonia in two patients, and urinary tract infection in one patient. Bacteremia was caused by Pseudomonas aeruginosa in two patients and Klebsiella pneumoniae in the remaining two patients. Three patients died within 30 days, and one patient suffering from persistent P. aeruginosa infection died within 15 days.
During the second period, the GM index was >0.5 in 46 of 50 (92%) patients receiving G1. The mean GM level was 2.02 (range, 0.18-6.68). Among the patients, 33 were male (66%); 27 had a relapse; 14 had a newly diagnosed disease, and nine were in remission. Allogeneic HSCT was performed in nine patients, whereas autologous HSCT was performed in 12 patients. Of the patients, 30 received various antifungal agents including posaconazole (n = 10), fluconazole (n = 10), voriconazole (n = 8), and caspofungin (n = 2) before serum GM test. A CT scan was performed in 13 out of 41 patients (31.7%) that revealed an invasive fungal infection. Moreover, the rate of CT scan was significantly higher in serum GM positive patients than those of GM negative (Table 1 ). The mean duration of GM positivity after initiation of piperacillin/tazobactam was 3.0 ± 1.6 days, whereas the mean duration of GM negativity after withdrawal of piperacillin/tazobactam was 4.6 ± 3.1 days. The mean GM level in patients received G1 was higher than those receiving original piperacillin/tazobactam (P < .001) ( Table 1 ).
Univariate analysis revealed that rates of the CT scan and GM positivity were higher in patients that received G1 compare to those received original piperacillin/tazobactam; the rate of MM was lower in patients that received G1 (Table 1) . No patients with MM had false positivity (FP) or false negativity (FN). In multivariate analysis, the odds ratio for GM positivity was found to be 391 times higher in patients receiving G1 than those received original piperacillin/tazobactam.
In addition, an in vitro analysis was performed on GM levels of two generic and one original piperacillin/tazobactam vials. The high GM index was found in G1 (2.93) and human serum treated (S-G1) (5.89) vials. The GM level was <0.5 in G2 (0.12-0.21) and original piperacillin/tazobactam (O1) (0.21-0.29) vials. The mean GM level was 1.93 ± 1.29 for positive control and 0.22 ± 0.05 for negative control. G1, one of the generic formulations, had high GM levels in both the serum physiologic and with human sera (S) (Fig. 1) .
The rate of FP in the serum GM test was 56% in patients receiving G1; however, no false positive was detected in patients receiving original piperacillin/tazobactam (P < .001). On the other hand, FN rate of serum GM test was 5.7% in patients receiving original piperacillin/tazobactam; however, no false negativity was detected in the patients using G1 (P = .167). Moreover, there was no difference in terms of FP of serum GM between using and not using mould active antifungal (43.3% vs. 27.3%, respectively; P = .132).
Discussion
The objective of this study was to investigate the effects of the original and generic piperacillin/tazobactam formulations on GM level. Out of 50 patients receiving G1, 92% had serum GM positivity, and the rate of FP was 56% in G1 group. Out of 35 patients receiving original piperacillin/tazobactam, 2.9% had serum GM positivity, and 5.7% had FN rate in GM assays. The in vitro analysis showed a higher rate of GM positivity that was detected in G1 vial (Fig. 1) . These vials might have become contaminated with GM.
According to the literature, many studies have been published on the interaction between serum GM and piperacillin/tazobactam, in particular prior to 2006. 5, 17 A piperacillin/tazobactam-related FP for serum GM is a matter of debate because many studies have asserted no apparent relationship with piperacillin/tazobactam. 7, 18, 19 It has been recently argued that the new piperacillin/tazobactam formulation that contains EDTA does not lead to false GM positivity. 6 The concern for false serum GM positivity has been retained due to the usage of generic formulas that play a crucial economic role in the low and middle income countries healthcare systems. 6 Although the antimicrobial effects of the generic drugs are noninferior to original drug, unexpected side effects may occur such as interaction with serum GM antigen. 20 The interaction between piperacillin/tazobactam and GM may vary among different generic piperacillin/tazobactam brands even in different batches. 21 For instance, a study reported that one generic piperacillin/tazobactam formula from Korea was not associated with false serum GM positivity, 22 while a study from France reported that false positive GM results had a significant relationship with one out of three piperacillin/tazobactam products. 9 In this study, one generic piperacillin/tazobactam formula was used for patients in the study period whereas G1 use was associated to high GM levels. Another issue that is considered to be responsible for GM positivity is the blood sampling time because the serum GM level may change if the blood sample is taken during piperacillin/tazobactam infusion. 15 During this study, all blood samples from patients were drawn between 7:00 and 9:00 AM by the same phlebotomist, while piperacillin/tazobactam infusion was performed from 6:00 to 9:00 AM. The same procedure for blood sampling was followed in both first and second periods. The third issue is that the use of mould active antifungal drugs affecting the serum GM index results. In a study, it was reported that the positive predictive value of GM positivity was 12% and concluded that GM could be useful in a case of clinical suspicion of IA. 11, 23 In our study, there was no significant difference in FP between the groups using or not using mould active antifungal agents (43.3% vs. 27.3%, respectively). In another study, 86% of 90 piperacillin/tazobactam vials were reported to be positive for serum GM index and false positive results have been explained by bimodal distribution. 24 However, all five generic piperacillin/tazobactam batches had no false-positivity of GM index in a Brazilian study, especially when the vials were diluted with human serum. 21 GM index positivity may be affected by different parties of piperacillin/tazobactam so that anticipation of false-positivity of GM is difficult. In our study, two generic and one original piperacillin/tazobactam vials were compared in terms of GM index positivity; one generic piperacillin/tazobactam formula had high level of GM index. The FP rate of GM has been found 3.59 times higher in patients with MM in a Korean study. 25 However, our finding showed that the rate of MM was more frequent in patients receiving original piperacillin/tazobactam than those receiving G1, and thus the rate of GM positivity was lower in patients with MM (Table 1) . No patients with MM had FP. In our study as no comprehensive analysis was performed in patients with MM, it might not be possible to perform head-to-head comparison between studies.
The disadvantages of false GM positivity include unnecessary antifungal administration, unreliable GM results and redundant advanced study. This study showed that serum GM positivity caused an increase in the rate of chest CT scan. Those patients using G1 had a 391-fold increase in the risk for false GM positivity.
In conclusion, all physicians should be aware of the false positive GM results in patients with concomitant piperacillin/tazobactam use, particularly in those using generic formulas. To identify the probability of false GM positivity, selected piperacillin/tazobactam vials in each batch may be inspected for GM positivity prior purchasing.
